Magnolia Medical Technologies
2001 Sixth Avenue
About Magnolia Medical TechnologiesMagnolia Medical is a medical device company that develops and manufactures innovative blood and bodily fluid collection devices that significantly improve the accuracy, consistency and predictability of critical in-vitro diagnostic (IVD) tests. False positive and false negative laboratory test results in the acute care setting create confusion and uncertainty that commonly lead to inappropriate, unnecessary treatments. These misdiagnoses often significantly increase utilization of antibiotics and associated complications as well as patient length of stay and risk for healthcare-associated infections (HAIs). By mechanically eliminating human errors that cause erroneous test results through elegantly engineered bodily fluid collection devices, Magnolia Medical’s products significantly improve patient safety and reduce hospital costs. The total potential market for Magnolia Medical’s technology exceeds $1.5 billion annually.
Founders: Richard G. Patton and Greg Bullington
Founder and CEO: Greg Bullington
Please click here for Magnolia Medical job opportunities.
18 articles with Magnolia Medical Technologies
Magnolia Medical Technologies, Inc. – the trusted solution for reducing blood culture contamination – today announced the launch of its new Steripath® Micro Initial Specimen Diversion Device®.
Magnolia Medical Technologies, Inc. today announced that the company was selected as the Innovative Technology Supplier of the Year by Vizient Inc. The award was presented in a virtual Awards Ceremony as part of the 2020 Vizient Connections Education Summit.
Magnolia Medical Launches Mission to ZERO™ Aimed at Resetting the National Blood Culture Contamination Benchmark
Magnolia Medical Technologies, Inc. today announced the launch of Mission to ZERO, a nationwide initiative to create greater awareness of the patient safety and antibiotic-associated risks caused by false-positive diagnostic test results for sepsis.
Magnolia Medical announced today the launch of the new Steripath® Gen2 Initial Specimen Diversion Device® with integrated syringe.
Reducing false positive sepsis tests creates capacity for critical PCR lab equipment and increases bed availability
Products become the first and only indicated to reduce blood culture contamination
12-month initiative demonstrates improved patient care and decreased hospital costs by reducing blood culture contamination
Magnolia Medical Technologies and The Center for Phlebotomy Education announced the expansion of their training and education partnership dedicated to the prevention of blood culture contamination.
Reducing False Positive Results for Sepsis with Steripath Improves Economic and Clinical Outcomes, Study Reports
Findings published in the Journal of Hospital Infection highlight the associated positive impacts of Magnolia Medical Technologies' novel Initial Specimen Diversion Device (ISDD)
Kurin Inc. responds to comments made by Greg Bullington, CEO of Magnolia Medical, in a letter Magnolia published regarding their patent-infringement lawsuit against Kurin.
Steripath® is the Only Technology of its Kind Supported by Independent Published Studies to Improve Sepsis Testing Accuracy
Matthew B. Lehr has been named Intellectual Property Special Counsel and will advise the company on intellectual property (IP) strategy and enforcement matters.
Kurin Inc., the inventor and manufacturer of Kurin® blood culture collection sets, responded to a patent-infringement lawsuit brought against Kurin by Magnolia Medical.
Cost-benefit analysis by the University of Houston College of Pharmacy highlights clinical and economic benefits of novel device
Magnolia Medical Launches Steripath Gen2 Best Practice Blood Culture Kit With Financially-Backed Clinical Performance Guarantee
The blood culture kit combines the Steripath Gen2 Initial Specimen Diversion Device® and additional required supplies in a convenient kit for the collection of blood culture samples that are virtually contamination-free.
Kurin Inc. has sued Magnolia Medical Technologies in the U.S. District Court for the Southern District of California for violations of the Lanham Act.
Magnolia Medical Technologies Announces Additional Funding Of $7.25 Million To Expand Use Of SteriPath For Sepsis Blood Testing